Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non–muscle-invasive bladder cancer using multi-layered –omics studies DOI Creative Commons
Murat Akand, Tatjana Jatsenko, Tim Muilwijk

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Oct. 21, 2024

Bladder cancer (BC) is the most common malignancy of urinary tract. About 75% all BC patients present with non-muscle-invasive (NMIBC), which up to 70% will recur, and 15% progress in stage grade. As recurrence progression rates NMIBC are strongly associated some clinical pathological factors, several risk stratification models have been developed individually predict short- long-term risks disease progression. The stratified into four groups as low-, intermediate-, high-risk, very high-risk by European Association Urology (EAU). Significant heterogeneity terms oncological outcomes prognosis has observed among within same EAU group, partly attributed intrinsic at molecular level. Currently, we a poor understanding how distinguish intermediate- (very-)high-risk from those more benign course lack predictive/prognostic tools that can specifically stratify them according their pathologic properties. There an unmet need for developing accurate scoring system considers treatment they receive after TURBT enable better further follow-up regimens selection, based also on response prediction treatment. Based these facts, employing multi-layered –omics (namely, genomics, epigenetics, transcriptomics, proteomics, lipidomics, metabolomics) immunohistopathology approach, hypothesize decipher this disease. A combination different – omics provide detailed multi-dimensional characterization tumor represent broad spectrum phenotypes, help NMIBC. We think combinatorial multi -omics approach potential improve higher precision develop feature-based algorithm stratifying properly guiding therapeutic interventions personalized manner.

Language: Английский

Genipin—Simple but Significant Bioactive Iridoid for Therapeutical Application and Beyond: A Review DOI Creative Commons
Danuta Sobolewska, Agnieszka Galanty, Karolina Grabowska

et al.

Life, Journal Year: 2025, Volume and Issue: 15(2), P. 159 - 159

Published: Jan. 23, 2025

Genipin is a non-glycosidic iridoid isolated mainly from the fruits of Gardenia jasminoides and Genipa americana. It active ingredient in extracts these plants, responsible for their anti-inflammatory hepatoprotective effects. In several vitro tests, its anti-proliferative activity against tumour cell lines has been demonstrated, due to ability specifically inhibit UCP2 protein STAT3 activation, significant increase cytotoxicity anticancer drugs was observed co-treatment with genipin. recent years, importance genipin increased possibility using this as biocompatible low potent crosslinking agent manufacture dressings, tissue engineering, component drug carrier system production food packaging. also substrate blue pigment used additive fabric pigment, other applications. Due documented cases hepatotoxicity, derived it are being investigated effective safe therapeutic non-drug use. The current paper discusses selected aspects chemistry, use interesting compound.

Language: Английский

Citations

1
From Pathogenesis to Precision Medicine: Transformative Advances in Research and Treatment of Ameloblastoma DOI Creative Commons
Zhao Zhang, Gan Xiong, Cheng Wang

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217448 - 217448

Published: Jan. 1, 2025

Language: Английский

Citations

0
Current Landscape of Hypoxia in Thyroid Cancer Pathogenesis and Treatment DOI

Jianhong Ye,

Liang Chen

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104719 - 104719

Published: April 1, 2025

Language: Английский

Citations

0
Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non–muscle-invasive bladder cancer using multi-layered –omics studies DOI Creative Commons
Murat Akand, Tatjana Jatsenko, Tim Muilwijk

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Oct. 21, 2024

Bladder cancer (BC) is the most common malignancy of urinary tract. About 75% all BC patients present with non-muscle-invasive (NMIBC), which up to 70% will recur, and 15% progress in stage grade. As recurrence progression rates NMIBC are strongly associated some clinical pathological factors, several risk stratification models have been developed individually predict short- long-term risks disease progression. The stratified into four groups as low-, intermediate-, high-risk, very high-risk by European Association Urology (EAU). Significant heterogeneity terms oncological outcomes prognosis has observed among within same EAU group, partly attributed intrinsic at molecular level. Currently, we a poor understanding how distinguish intermediate- (very-)high-risk from those more benign course lack predictive/prognostic tools that can specifically stratify them according their pathologic properties. There an unmet need for developing accurate scoring system considers treatment they receive after TURBT enable better further follow-up regimens selection, based also on response prediction treatment. Based these facts, employing multi-layered –omics (namely, genomics, epigenetics, transcriptomics, proteomics, lipidomics, metabolomics) immunohistopathology approach, hypothesize decipher this disease. A combination different – omics provide detailed multi-dimensional characterization tumor represent broad spectrum phenotypes, help NMIBC. We think combinatorial multi -omics approach potential improve higher precision develop feature-based algorithm stratifying properly guiding therapeutic interventions personalized manner.

Language: Английский

Citations

1